Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SELLAS Life Sciences (SLS) EBITDA (2020 - 2023)

Historic EBITDA for SELLAS Life Sciences (SLS) over the last 7 years, with Q4 2023 value amounting to -$8.2 million.

  • SELLAS Life Sciences' EBITDA rose 1343.43% to -$8.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$37.9 million, marking a year-over-year increase of 972.82%. This contributed to the annual value of -$37.9 million for FY2023, which is 972.82% up from last year.
  • Latest data reveals that SELLAS Life Sciences reported EBITDA of -$8.2 million as of Q4 2023, which was up 1343.43% from -$9.4 million recorded in Q3 2023.
  • Over the past 5 years, SELLAS Life Sciences' EBITDA peaked at -$2.2 million during Q1 2021, and registered a low of -$16.7 million during Q1 2022.
  • Over the past 4 years, SELLAS Life Sciences' median EBITDA value was -$7.7 million (recorded in 2022), while the average stood at -$7.6 million.
  • Its EBITDA has fluctuated over the past 5 years, first surged by 4475.89% in 2021, then plummeted by 64543.43% in 2022.
  • Over the past 4 years, SELLAS Life Sciences' EBITDA (Quarter) stood at -$4.2 million in 2020, then tumbled by 179.37% to -$11.6 million in 2021, then grew by 18.7% to -$9.4 million in 2022, then grew by 13.43% to -$8.2 million in 2023.
  • Its last three reported values are -$8.2 million in Q4 2023, -$9.4 million for Q3 2023, and -$9.0 million during Q2 2023.